Roadmap

Abcely is shaping a pipeline designed to unlock new therapeutic and market opportunities.

ABC-101

Solid Tumor – First Indication Colorectal Cancer

First-in-class anti-CEA sIgA for colorectal cancer with enhanced mucosal targeting and tumor penetration.

Status

1.9M

New Cases /Year Worldwide

$ 10•3 B

Therapy Market by 2032

ABC-201

Endometriosis

First-in-Class Treatment Strategy Novel approach for endometriosis targeting key disease mechanisms with mucosal-specific sIgA.

300M

Patients
Worldwide

$ 5.4 B

Therapy Market by 2034

ABC-301

Inflammatory Bowel Disease

Bio-better oral anti-TNFα with improved efficacy and safety profile through sIgA format

6M

Patients
Worldwide

$ 41 B

Market
by 2032

Growth & Strategic Opportunities

Licensing & Strategic Partnerships

Rapid Paratope Grafting Technology

Multiple Value Inflection Points

Roadmap and Value Creation

Strategic Partnerships

Early-stage licensing and industrial collaborations

Early revenue generation

Reduces financial risk

The announcement of a cancer diagnosis is a tsunami that stops a life in its tracks, leaving indelible scars and even shattering it completely. Treatment offers repair and reconstruction, healing the body and restoring its integrity. Treatment through remission and healing gives a second chance at life, which takes on an enhanced, unprecedented and new value that every patient feels after being so afraid of losing it.

The ABCELY logo was inspired by the Japanese tradition of ceramic repair, which, instead of hiding fractures and scars, sublimates them by highlighting them in gold, creating a work of art of immense value while restoring its original functionality. Life is never the same after such an experience, both in body and soul. With humility, our logo seeks to symbolize a life rebuilt and sublimated after such a devastating illness.